Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

SARS-CoV-2 infection, and resulting disease, COVID-19, has a high mortality amongst patients with haematological malignancies. Global vaccine rollouts have reduced hospitalisations and deaths, but vaccine efficacy in patients with haematological malignancies is known to be reduced. The UK-strategy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Lucy B., O’Dell, Gillian, Vourvou, Eleni, Palanicawandar, Renuka, Marks, Sasha, Milojkovic, Dragana, Apperley, Jane F., Loaiza, Sandra, Claudiani, Simone, Bua, Marco, Hockings, Catherine, Macdonald, Donald, Chaidos, Aris, Pavlu, Jiri, Cooper, Nichola, Fidler, Sarah, Randell, Paul, Innes, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662771/
https://www.ncbi.nlm.nih.gov/pubmed/36376307
http://dx.doi.org/10.1038/s41467-022-34657-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662771/
https://www.ncbi.nlm.nih.gov/pubmed/36376307
http://dx.doi.org/10.1038/s41467-022-34657-z

Ejemplares similares